Navigation Links
Martek Announces Fourth Quarter and FY 2010 Financial Results
Date:12/8/2010

COLUMBIA, Md., Dec. 8, 2010 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) today announced its financial results for the fourth quarter and fiscal year ended October 31, 2010. Total revenues for the fourth quarter were $119.1 million, up 36% from the fourth quarter of fiscal 2009. Fourth quarter non-GAAP earnings per share (EPS) were $0.41, a 24% increase from $0.33 per diluted share in last year's fourth quarter.  For the full year 2010, revenues increased 30% to $450.0 million, and full year non-GAAP EPS were $1.55, an increase of 27% versus 2009.  Non-GAAP EPS for the fourth quarter and full year 2010 exclude, for the applicable periods, certain acquisition and restructuring charges (see Table II "Reconciliation of GAAP to Non-GAAP Net Income Measure" below).  On a GAAP basis, earnings (loss) per share were ($0.18) and $0.83 for the fourth quarter and full year 2010, respectively.  Revenue and earnings for the fourth quarter include the results of Amerifit Brands ("Amerifit" or "branded consumer health products"), and revenue and earnings for the full year fiscal 2010 include the results of Amerifit since the February 12, 2010 date of acquisition by Martek.

Commenting on the quarter and year, Chief Executive Officer Steve Dubin said, "Martek's fourth quarter came in at the high end of our expectations and concluded a year of many accomplishments for Martek.  Revenue grew across all business segments in 2010, our core infant formula ingredients business was strengthened through the extension of the terms of two of our key infant formula sole source supply agreements, and significant improvements on the operational side of the business were implemented which helped drive growth in both margins and income.  In addition, we expanded our business platform through the acquisition of Amerifit, and made significant progress o
'/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Martek to Present at Upcoming Citi Small / Mid Cap Conference
2. Martek to Present at Upcoming UBS Conference
3. Martek Announces Third Quarter FY 2010 Financial Results
4. Martek Announces Fourth Quarter and FY 2009 Financial Results
5. Martek Signs Sole-Source Supply Agreement with Fonterra
6. Martek to Announce Fourth Quarter and Fiscal Year 2009 Results
7. Martek Announces Addition to Its Board of Directors
8. Martek to Present at Two Upcoming Investor Conferences
9. Martek Announces Settlement of Patent Dispute with Capsugel France
10. Federal Circuit Rules in Marteks Favor in Appeal of Patent Infringement Case
11. Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... A recent study from researchers in ... find that those who took probiotics were able to run ... study showed that in extreme heat conditions, probiotics were able ... acne treatment explains what this new discovery means ... their skin condition. , While researchers tote the benefits ...
(Date:5/21/2013)... -- First patients dosed with PSX1002, an ... using Prosonix, particle engineering platform Prosonix, an ... Respiratory Medicines by Design , has initiated a ... its effect on lung function and the safety of ... severe chronic obstructive pulmonary disease (COPD). The first two ...
(Date:5/21/2013)... May 21, 2013 Custom Learning ... reporting eLearning solution using Tin Can API combined ... tool. CLD is a leading developer of training ... device companies worldwide. , Tin Can API ... helps learners and trainers more accurately measure the ...
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... exhibiting for the 13th consecutive year at the ... 2013 Conference and Expo. The conference brings together ... healthcare technologies. This year’s event will be held ... , The three-day event draws over 1,500 healthcare ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2
... It's been a long campaign season, and you've been poked ... national press corps member. John Kerry drank a beer at ... at your local kindergarten. Dick Cheney was spotted more in ... in the last four years. John Edwards has been in ...
... drug purification products Business filings serves ... dip in third-quarter earnings from mild weather ... Wisconsin-based Analogix joins French company to ... maker of drug-purification devices based in Burlington, Wisconsin, has ...
... more hours in the day so I can get more done (like ... We "fall back" into standard time and get another hour. But what ... my desk, which I always promise to do when I have more ... wanted to share in this column. Here they are, in no particular ...
Cached Biology Technology:Twenty ways you can tell this campaign has finally pushed you over the edge 2Tech Digest: whats moving in the Midwest (11/1/04) 2Music, mail, databases and printing from a technologists desk 2Music, mail, databases and printing from a technologists desk 3
(Date:5/21/2013)... The largest gathering of biomass experts , ... , When? 03-07 June 2013 ... scientific research, resource assessment, market and policy developments, manufacturing ... the world and benefiting from its 2013 edition from ... more than 60 countries, more than 240 plenary and ...
(Date:5/21/2013)... May 21, 2013 Royal Philips Electronics (NYSE: ... world,s first portable ultrasound with Philips, industry leading Live ... The CX50 xMATRIX with available Live 3D TEE and ... at the EuroPCR, official meeting for the European ... Since its launch in 2012, Philips CX50 xMATRIX ...
(Date:5/20/2013)... antibiotic colistin are also commonly resistant to antimicrobial ... a study in mBio , the online ... Cross-resistance to colistin and host antimicrobials LL-37 and ... attack, could mean that patients with life-threatening multi-drug ... immune response. Colistin is a last-line drug for ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... Alabama used worms to reel in information that they hope ... may be exploited to treat epilepsy. In a new research ... the researchers explain how the transparent roundworm, C. elegans ... transport of a molecule (gamma-aminobutyric acid or "GABA") that if ...
... b3c newswire / - Critical Outcome Technologies ... from animal experiments carried out at a prominent Canadian ... to the already impressive data package for COTI-2, demonstrating ... first line therapies with low toxicity in seven different ...
... the primary cause of cancer mortality in children. Even ... tremendously from the stressful treatment which can be harmful ... need for target-oriented, gentle treatment methods. The most important ... approximately one hundred young patients each year in Germany, ...
Cached Biology News:More than fish bait: Worms unlock secrets to new epilepsy treatments 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 4Germany starts its part in the International Cancer Genome Project 2Germany starts its part in the International Cancer Genome Project 3Germany starts its part in the International Cancer Genome Project 4
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Biology Products: